Minimal functional driver gene heterogeneity among untreated metastases - PubMed
- ️Mon Jan 01 2018
. 2018 Sep 7;361(6406):1033-1037.
doi: 10.1126/science.aat7171.
Alvin P Makohon-Moore 3 , Jeffrey M Gerold 2 , Alexander Heyde 2 , Marc A Attiyeh 3 , Zachary A Kohutek 4 , Collin J Tokheim 5 , Alexia Brown 3 , Rayne M DeBlasio 3 , Juliana Niyazov 3 , Amanda Zucker 3 , Rachel Karchin 5 6 , Kenneth W Kinzler 7 8 9 , Christine A Iacobuzio-Donahue 3 10 , Bert Vogelstein 7 8 9 11 , Martin A Nowak 12 13
Affiliations
- PMID: 30190408
- PMCID: PMC6329287
- DOI: 10.1126/science.aat7171
Minimal functional driver gene heterogeneity among untreated metastases
Johannes G Reiter et al. Science. 2018.
Abstract
Metastases are responsible for the majority of cancer-related deaths. Although genomic heterogeneity within primary tumors is associated with relapse, heterogeneity among treatment-naïve metastases has not been comprehensively assessed. We analyzed sequencing data for 76 untreated metastases from 20 patients and inferred cancer phylogenies for breast, colorectal, endometrial, gastric, lung, melanoma, pancreatic, and prostate cancers. We found that within individual patients, a large majority of driver gene mutations are common to all metastases. Further analysis revealed that the driver gene mutations that were not shared by all metastases are unlikely to have functional consequences. A mathematical model of tumor evolution and metastasis formation provides an explanation for the observed driver gene homogeneity. Thus, single biopsies capture most of the functionally important mutations in metastases and therefore provide essential information for therapeutic decision-making.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Conflict of interest statement
Competing interests: K.W.K. and B.V. are founders of Personal Genome Diagnostics. B.V. and K.W.K. are on the Scientific Advisory Board of Sysmex-Inostics. B.V. is also on the Scientific Advisory Boards of Exelixis GP. These companies and others have licensed technologies from Johns Hopkins, and K.W.K. and B.V. receive equity or royalties from these licenses. The terms of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies.
Figures
![Fig. 1.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d0/6329287/ed5e095ecac3/nihms-1004938-f0001.gif)
The original clone (green cells) contains three driver gene mutations (D1, D2, D3). Brown, yellow, and red cells acquired additional driver mutations during the growth of the primary tumor (PT) and may expand to form detectable subpopulations (brown) which can seed metastases. Top panels illustrate seeding subpopulations and biopsies (blue circles) of different regions (R1, R2) of the PT and of distinct metastases (M1, M2). Bottom panels illustrate reconstructed cancer phylogenies from those biopsies. (A) Original clone seeds all metastases. All metastases share same founding driver mutations. Subclones with additional driver mutations (D4) evolve too late to seed metastases, but might be detectable in the PT. (B) A single highly metastatic subclone evolves and gives rise to all metastases. All metastases share same founding driver mutations. (C) A new subclone with an additional driver mutation (D4) evolves and independently seeds metastases. PT regions and metastases exhibit driver mutation heterogeneity.
![Fig. 2.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d0/6329287/c181abba2930/nihms-1004938-f0002.gif)
(A) Twenty patients with 76 untreated metastases. Thirteen patients acquired mutations in putative driver genes along the MetBranch (MB) while seven did not. (B) Inferred phylogeny of a colorectal cancer exhibits inter-metastatic driver mutation heterogeneity. Nonsynonymous mutations in driver genes are denoted in orange. Percentages denote branch confidence. Integers denote number of point mutations per branch. Table shows predicted functional effects of mutations in driver genes. Heterogeneous driver mutations were predicted to have no functional effect or were likely sequencing artifacts (low coverage and low VAF across all sites). MetTrunk (MT) denotes that variant was acquired on the trunk of all metastases. Sample origin: rectum: PT1–5; liver: Met1–6.
![Fig. 3.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d0/6329287/d3ed65e59d08/nihms-1004938-f0003.gif)
(A) Ratio of driver gene mutations to nonsynonymous mutations is enriched by 42-fold along trunks compared to branches. Orange diamond denotes mean, black bar denotes median (two-sided paired t-test P = 0.004). (B) Fraction of nonsynonymous variants in driver genes along MetTrunk in COSMIC was 38% compared to 16% along MetBranch (two-sided Fisher’s exact test P = 0.025). (C) Relative occurrence of variants in driver genes along MetTrunk in individual COSMIC samples was 0.32% compared to 0.0016% along MetBranch (two-sided Wilcoxon rank-sum test P = 0.008). (D) VEP inferred that 30% and 6% of driver gene mutations were of high impact along MetTrunk and MetBranch, respectively (two-sided Fisher’s exact test P = 0.006). (E-F) FATHMM (value below −0.75 indicates likely driver mutation) and CHASMplus predicted increased functional consequences for variants in driver genes in MetTrunk. Two-sided Wilcoxon rank-sum tests were used. Thick black bars denote 90% confidence interval. No other statistically significant differences were observed. Numbers in brackets denote number of variants in each group. * indicates P < 0.05, ** P < 0.01, *** P < 0.001.
![Fig. 4.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d0/6329287/290a7e038e5e/nihms-1004938-f0004.gif)
(A) Primary tumor expands stochastically from a single advanced cancer cell and seeds metastases. Cells of original clone (green) divide at rate b0 and die at rate d per day. Additional driver mutations increase the birth rate to b1 = b0(1+s), where s denotes the relative driver advantage (b1 ≥ b0, q = q1; B-E), or increase the dissemination rate (q1 ≥ q0, b1 = b0; F). (B) Representative model realizations for typical parameter values. Growth rate r0 = 1.24% per day, s = 0.4%, dissemination rate q0 = 10−7 per cell per day. (C) Distribution of metastases detection times for parameter values in B. Numbers denote mean ± standard deviation. Colored marks show mean detection times of first, second, third, and fourth metastases seeded by the corresponding subclone (SC). (D-F) Probability of distinct driver mutations among four metastases. Green dashed lines depict bounds separating parameter regions of likely inter-metastatic driver homogeneity from heterogeneity. Orange dotted lines denote s = 0.4%. (D) Fixed q0 = 10−7. (E) Fixed death-birth rate ratio d/b0 = 0.95. (F) Fixed q0 = 10−7. Other parameter values: d = 0.2475, driver mutation rate u = 3.4 10−5 per cell division.
Similar articles
-
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, de Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Cottu P, Reis-Filho JS. Ng CKY, et al. Clin Cancer Res. 2017 Aug 1;23(15):4402-4415. doi: 10.1158/1078-0432.CCR-16-3115. Epub 2017 Mar 28. Clin Cancer Res. 2017. PMID: 28351929 Free PMC article.
-
Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, Chatterjee K, Wong F, Jiao Y, Kohutek ZA, Hong J, Attiyeh M, Javier B, Wood LD, Hruban RH, Nowak MA, Papadopoulos N, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Makohon-Moore AP, et al. Nat Genet. 2017 Mar;49(3):358-366. doi: 10.1038/ng.3764. Epub 2017 Jan 16. Nat Genet. 2017. PMID: 28092682 Free PMC article.
-
An analysis of genetic heterogeneity in untreated cancers.
Reiter JG, Baretti M, Gerold JM, Makohon-Moore AP, Daud A, Iacobuzio-Donahue CA, Azad NS, Kinzler KW, Nowak MA, Vogelstein B. Reiter JG, et al. Nat Rev Cancer. 2019 Nov;19(11):639-650. doi: 10.1038/s41568-019-0185-x. Epub 2019 Aug 27. Nat Rev Cancer. 2019. PMID: 31455892 Free PMC article. Review.
-
Hu Z, Li Z, Ma Z, Curtis C. Hu Z, et al. Nat Genet. 2020 Jul;52(7):701-708. doi: 10.1038/s41588-020-0628-z. Epub 2020 May 18. Nat Genet. 2020. PMID: 32424352 Free PMC article.
-
The challenge of targeting metastasis.
Fidler IJ, Kripke ML. Fidler IJ, et al. Cancer Metastasis Rev. 2015 Dec;34(4):635-41. doi: 10.1007/s10555-015-9586-9. Cancer Metastasis Rev. 2015. PMID: 26328524 Free PMC article. Review.
Cited by
-
Yaegashi M, Iwaya T, Sasaki N, Fujita M, Ju Z, Siwak D, Hachiya T, Sato K, Endo F, Kimura T, Otsuka K, Sugimoto R, Sugai T, Liotta L, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. Yaegashi M, et al. Br J Cancer. 2021 Apr;124(9):1556-1565. doi: 10.1038/s41416-021-01266-4. Epub 2021 Mar 3. Br J Cancer. 2021. PMID: 33658639 Free PMC article.
-
Fazio M, van Rooijen E, Mito JK, Modhurima R, Weiskopf E, Yang S, Zon LI. Fazio M, et al. Pigment Cell Melanoma Res. 2021 May;34(3):641-647. doi: 10.1111/pcmr.12937. Epub 2020 Nov 17. Pigment Cell Melanoma Res. 2021. PMID: 33064882 Free PMC article.
-
Phenotypic plasticity and genetic control in colorectal cancer evolution.
Househam J, Heide T, Cresswell GD, Spiteri I, Kimberley C, Zapata L, Lynn C, James C, Mossner M, Fernandez-Mateos J, Vinceti A, Baker AM, Gabbutt C, Berner A, Schmidt M, Chen B, Lakatos E, Gunasri V, Nichol D, Costa H, Mitchinson M, Ramazzotti D, Werner B, Iorio F, Jansen M, Caravagna G, Barnes CP, Shibata D, Bridgewater J, Rodriguez-Justo M, Magnani L, Sottoriva A, Graham TA. Househam J, et al. Nature. 2022 Nov;611(7937):744-753. doi: 10.1038/s41586-022-05311-x. Epub 2022 Oct 26. Nature. 2022. PMID: 36289336 Free PMC article.
-
Bechard ME, Smalling R, Hayashi A, Zhong Y, Word AE, Campbell SL, Tran AV, Weiss VL, Iacobuzio-Donahue C, Wellen KE, McDonald OG. Bechard ME, et al. Nat Commun. 2020 Aug 13;11(1):4055. doi: 10.1038/s41467-020-17839-5. Nat Commun. 2020. PMID: 32792504 Free PMC article.
-
The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment.
Brady SW, Ma X, Bahrami A, Satas G, Wu G, Newman S, Rusch M, Putnam DK, Mulder HL, Yergeau DA, Edmonson MN, Easton J, Alexandrov LB, Chen X, Mardis ER, Wilson RK, Downing JR, Pappo AS, Raphael BJ, Dyer MA, Zhang J. Brady SW, et al. Mol Cancer Res. 2019 Apr;17(4):895-906. doi: 10.1158/1541-7786.MCR-18-0620. Epub 2019 Jan 16. Mol Cancer Res. 2019. PMID: 30651371 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources